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Abstract
Angiogenesis is an essential event in the development of synovial inflammation in rheuma-
toid arthritis (RA). The aim of the current study was to investigate the expression of vasohibin-1,
a novel endothelium-derived vascular endothelial growth factor (VEGF)-inducible angiogenesis
inhibitor, in the RA synovium, and to test the effect of inflammatory cytokines on the expression
of vasohibin-1 by RA synovial fibroblasts (RASFs). Synovial tissue samples were obtained at
surgery from patients with osteoarthritis (OA) and RA, and subjected to immunohistochemistry
to investigate the expression and distribution of vasohibin-1 relevant to the degree of synovial
inflammation. In an in vitro analysis, RASFs were used to examine the expression of vasohibin-
1 and VEGF mRNA by real-time PCR after stimulation with VEGF or inflammatory cytokines
under normoxic or hypoxic conditions. The immunohistochemical results showed that vasohibin-
1 was expressed in synovial lining cells, endothelial cells, and synovial fibroblasts. In synovial
tissue, there was a significant correlation between the expression of vasohibin-1 and histological
inflammation score (p0.002, r0.842). In vitro, stimulation with VEGF induced the expression of
vasohibin-1 mRNA in RASFs under normoxic conditions, and stimulation with cytokines induced
vasohibin-1 mRNA expression under a hypoxic condition. These results suggest that vasohibin-1
was expressed in RA synovial tissue and might be regulated by inflammatory cytokines.
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Angiogenesis is an essential event in the development of synovial inﬂammation in rheumatoid arthritis 
(RA).  The aim of the current study was to investigate the expression of vasohibin-1,  a novel endothe-
lium-derived vascular endothelial growth factor (VEGF)-inducible angiogenesis inhibitor,  in the RA 
synovium,  and to test the eﬀect of inﬂammatory cytokines on the expression of vasohibin-1 by RA 
synovial ﬁbroblasts (RASFs).  Synovial tissue samples were obtained at surgery from patients with 
osteoarthritis (OA) and RA,  and subjected to immunohistochemistry to investigate the expression and 
distribution of vasohibin-1 relevant to the degree of synovial inﬂammation.  In an in vitro analysis,  
RASFs were used to examine the expression of vasohibin-1 and VEGF mRNA by real-time PCR after 
stimulation with VEGF or inﬂammatory cytokines under normoxic or hypoxic conditions.  The immu-
nohistochemical results showed that vasohibin-1 was expressed in synovial lining cells,  endothelial cells,  
and synovial ﬁbroblasts.  In synovial tissue,  there was a signiﬁcant correlation between the expression 
of vasohibin-1 and histological inﬂammation score (p＝0.002,  r＝0.842).  In vitro,  stimulation with 
VEGF induced the expression of vasohibin-1 mRNA in RASFs under normoxic conditions,  and stimu-
lation with cytokines induced vasohibin-1 mRNA expression under a hypoxic condition.  These results 
suggest that vasohibin-1 was expressed in RA synovial tissue and might be regulated by inﬂammatory 
cytokines.
Key words: angiogenesis,  vasohibin-1,  rheumatoid arthritis,  synovial membrane,  VEGF
heumatoid arthritis (RA) is a chronic inﬂamma-
tory disease characterized by progressive bone 
and joint destruction.  In RA,  angiogenesis plays a 
pivotal role in the pathogenesis of synovial inﬂamma-
tion,  maintaining the inﬂammatory synovial tissues,  
and providing the condition for inﬂammatory cell 
inﬁltration from the early stage of the disease [1,  2].  
Newly formed blood vessels allow the synovial tissue 
to cope with increased demand of oxygen and nutrients 
by inﬁltrating CD4＋ T cells,  B cells,  macrophages,  
and the proliferated synovial lining cells.  In fact,  the 
hypoxic nature of the RA synovium has been conﬁrmed 
by measuring oxygen tension in samples of synovial 
ﬂuids obtained from patients with RA [3,  4].  This 
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hypoxic condition stimulates the activation of tran-
scriptional regulators,  such as hypoxia inducible fac-
tor (HIF) [5].  HIF induces angiogenesis in arthritis 
[6] by directly inducing the expression of a broad 
range of pro-angiogenic factors,  such as vascular 
endothelial growth factor (VEGF) and its receptors 
ﬂk-1,  ﬂt-1,  and angiopoietin,  as well the angiopoietin 
receptor tie-2,  all of which are upregulated in the RA 
synovium [6-8].
　 Among the various growth factors promoting angio-
genesis,  VEGF plays perhaps the important roles in 
the process of angiogenesis by promoting endothelial 
cell migration,  proliferation,  and vascular permeabil-
ity in association with inﬂammation [9].  VEGF secre-
tion by RA synovial ﬁbroblasts (RASFs) and PBMCs 
from RA patients is up-regulated by inﬂammatory 
cytokines such as tumor necrosis factor-alpha (TNF-α) 
or interleukin-1-beta (IL-1β),  both of which are con-
sidered to be key cytokines in the pathogenesis of RA 
[10,  11].
　 A number of pro-angiogenic and anti-angiogenic 
factors regulate VEGF expression [12].  Vasohibin-1 
was originally identiﬁed from a microarray analysis 
designed to examine genes up-regulated by VEGF in 
endothelial cells [13],  and was considered to act as an 
endogenous negative feedback regulator of angiogene-
sis.  Vasohibin-1 is induced by VEGF-A and FGF-2,  
and inhibits angiogenesis in an autocrine manner [13,  
14].  Vasohibin-1 is expressed in the tissues of 
patients with endometrial cancer [15] and breast 
cancer [16],  and in the retina of patients with dia-
betic retinopathy [17].  These recent ﬁndings suggest 
that the levels of vasohibin-1 may be associated with 
the clinical activities and severity of various disorders.  
In addition,  therapeutic eﬀects of vasohibin-1 in tumor 
growth,  atherosclerosis and proliferative retinopathy 
models have also been reported [13,  18,  19].
　 In the present study,  we investigated the expres-
sion of vasohibin-1 in human synovial tissue for the 
ﬁrst time.  To examine the association between syn-
ovial inﬂammation and vasohibin-1 expression,  we 
investigated samples from patients with RA and also 
patients with osteoarthritis (OA) as a low-grade 
inﬂammation control.  Interestingly,  the expression of 
vasohibin-1 was observed in both the OA and RA 
synovium,  and the number of vasohibin-1-positive cells 
correlated with the degree of tissue inﬂammation.  
These ﬁndings further prompted us to investigate the 
mechanism of vasohibin-1 induction in synovial ﬁbro-
blasts.  The results suggested that vasohibin-1 expres-
sion might be up-regulated by VEGF under a normoxic 
condition,  and by the inﬂammatory cytokines under a 
hypoxic condition.
Materials and Methods
　 Immunohistochemistry. For the immunohis-
tochemical analysis,  fresh synovial tissues were 
obtained from the knee,  wrist or elbow joints of 12 
patients with RA (11 women and 1 man; mean age,  
63.9±8.1 years old) and 9 patients with OA (5 
women,  2 men,  and data not available in 2 samples;  
mean age,  69.7±8.7 years old) who were undergoing 
total knee,  wrist or elbow arthroplasty.  Informed 
written consent was obtained from all patients.  The 
diagnosis of RA was determined according to the 
revised 1987 criteria of the American College of 
Rheumatology (formerly,  the American Rheumatism 
Association) [20].  Immunohistochemistry was per-
formed as previously described [21] utilizing paraﬃn-
embedded sections.  Serial paraﬃn sections of the 
synovium (4µm) were deparaﬃnized,  rehydrated,  and 
incubated with 3ｵ H2O2 for 30min to block endoge-
nous peroxidase activity.  Sections were then incu-
bated for 30min at room temperature (RT) in a block-
ing solution of 10ｵ rabbit serum (Nichirei 
Biosciences,  Tokyo,  Japan),  and then incubated with 
mouse anti-human vasohibin-1 monoclonal antibody 
(4.0µg/ml; Tohoku University,  Sendai,  Japan) [13],  
anti-VEGF-A antibody (Millipore,  Billerica,  MA,  
USA; 1 : 800 dilution),  and anti-CD34 antibody (Dako,  
Copenhagen,  Denmark; 1 : 200 dilution) overnight at 
4℃,  followed by incubation with biotinylated second-
ary antibodies (Nichirei Biosciences) for 60min at 
RT.  Immunoperoxidase staining was conducted using 
a Vectastain ABC Elite kit (Vector Laboratories,  
Burlingame,  CA,  USA).  Diaminobenzidine was used 
as a chromogen.  All slides were counterstained with 
hematoxylin.
　 Histological examination. Following immu-
nostaining,  each section was evaluated under a light 
microscope in 5 randomly selected areas of the syn-
ovium at a magniﬁcation of×100 and the means of the 
inﬂammation scores and vasohibin-1 scores were cal-
culated.  The inﬂammation score was calculated as 
described previously [22] (Table 1).  The vasohibin-1 
350 Acta Med.  Okayama　Vol.  63,  No.  6Miyake et al.
2
Acta Medica Okayama, Vol. 63 [2009], Iss. 6, Art. 6
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss6/6
score in each area was determined according to the 
previously described method with some modiﬁcations 
[23].  In brief,  the number of positively stained cells 
was counted and evaluated using a 4-point scale: 0＝
no staining,  1＝localized staining,  2＝positively 
stained in more than 20ｵ of the cells,  3＝positively 
stained in more than 50ｵ of the cells,  and 4＝wide-
spread,  total staining of the synovial tissue.  The 
amount of VEGF was similarly determined in the same 
5 areas on the serial sections used for vasohibin-1 
staining.  The number of microvessels positively 
stained with CD34 was also counted in the same 5 
areas on the next serial section.
　 Isolation and culture of human RASFs.
With the patientsʼ written consent,  fresh synovial 
tissues were obtained from the knee,  elbow or wrist 
joints of 4 RA patients (4 women; mean age,  65.7±
6.0 years old) who underwent total knee,  elbow or 
wrist arthroplasty.  Tissues were minced and digested 
immediately with collagenase (Wako,  Osaka,  Japan) 
and DNase (Sigma-Aldrich,  St. Louis,  MO,  USA) at 
37℃,  as previously described [24].  Tissue debris 
was removed with a cell strainer,  and cells were 
washed twice with medium consisting of Dulbeccoʼs 
modiﬁed Eagleʼs medium (DMEM; Sigma-Aldrich) 
supplemented with 10ｵ fetal bovine serum (FBS;  
Life Technologies,  Rockville,  MD,  USA),  100IU/ml 
of penicillin,  and 100mg/ml of streptomycin (Life 
Technologies).  The resultant single cells were dis-
pensed into the wells of a 24-well microtiter plate 
(Costar,  Cambridge,  MA,  USA) at a density of 2×
106 cells/ml in 2ml of DMEM supplemented with 10ｵ 
FCS,  100IU/ml of penicillin,  and 100mg/ml of 
streptomycin.  The plates were incubated at 37℃ in a 
humidiﬁed atmosphere containing 5ｵ CO2.  Synovial 
tissue cell cultures were divided once weekly until the 
primary cultures had reached conﬂuence.  After the 
third passage,  the cells appeared to be morphologi-
cally homogeneous ﬁbroblast-like cells.
　 Real-time polymerase chain reaction (PCR) 
for the quantitative detection of vasohibin-1 and 
VEGF messenger RNA (mRNA). The cells 
were seeded at a density of 5×105/dish into a 6cm-
dish (Costar) containing 3ml of DMEM and 10ｵ FCS 
and were allowed to adhere at least 12h.  The cells 
were then incubated with FCS-free DMEM for 24h.  
Next,  the cells were stimulated with recombinant 
human VEGF (0.1nM; R&D Systems,  Minneapolis,  
MN,  USA),  or either or both recombinant human 
TNF-α (1ng/ml; R&D Systems) or recombinant 
human IL-1β (10ng/ml; R&D Systems) and incubated 
with or without hypoxia (1ｵ O2) under an atmosphere 
of 5ｵ CO2 for the time periods indicated below.  Cell 
viability in the 6cm-dish was evaluated at 12,  24,  
and 48h after cytokine or VEGF treatment.  Total 
RNA was isolated from cultured cells with an RNA 
isolation kit (RNeasy Mini kit; Qiagen,  Valencia,  CA,  
USA),  according to the manufacturerʼs instructions.  
The RNA was reverse-transcribed using ReverTra 
Ace (Toyobo,  Tokyo,  Japan).  The primer pair for 
vasohibin-1 was purchased from Nihon Idenshi 
Kenkyujo (Sendai,  Japan) and was as follows: 5ʼ
-CCATACCGAGTGTGCCTAC-3ʼ (forward) and 5ʼ
-AGAACTGTGTCCCTG-TGTGA-3ʼ (reverse).  
Primers for beta-actin and VEGF were purchased 
from Roche Diagnostics.  Real-time quantitative PCR 
reactions were performed on a LightCycler instru-
ment (Roche Diagnostics) using a LightCycler Fast-
Start DNA Master SYBR Green I kit (Roche 
Molecular Biochemicals,  Mannheim,  Germany) as 
recommended by the manufacturer.  The ﬁnal expres-
sion value was calculated by dividing the level of 
vasohibin-1 or VEGF mRNA expression by the level 
of beta-actin mRNA expression,  and each value at the 
basal time point was set as 1.  For all real-time PCR 
experiments,  cDNA samples were obtained from 3 
distinct lines of RASFs derived from three individual 
patients at passages 3-5,  and real-time PCR reactions 
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Table 1　 The grading system of the synovial membrane inﬂammation
Score Synovial lining cell hyperplasia Cellular inﬁltration Fibrosis of the lining cell layer
0 1-2 layers of cells Not present Normal
1 3-4 layers Mild Mild
2 5-6 layers Moderate and focal Moderate
3 6-7 layers Moderate and diﬀuse Marked
4 Over 7 layers Marked and diﬀuse Marked
3
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were repeated three times for each cDNA sample 
obtained from RASF.
　 Statistical analysis. Data were expressed as 
the means±SD.  Statistical analysis was performed 
using a one-way analysis of variance followed by either 
Fisherʼs least signiﬁcant diﬀerence test or the Mann-
Whitney U test,  using Statview-J 5.0 software (SAS 
Institute,  Cary,  NC,  USA); values of p＜0.05 were 
considered statistically signiﬁcant.
Results
　 Expression of vasohibin-1 in OA and RA 
synovial tissues. The inﬂammation scores of OA 
and RA synovial tissues were 2.60±0.94 and 5.68±
1.96,  respectively (Table 2).  The inﬂammation score 
was signiﬁcantly diﬀerent between the two groups (p
＝0.003).  Immunoreactivity for vasohibin-1 was 
detected in the synovial lining cells,  endothelial cells,  
and synovial ﬁbroblasts (Fig.  1A).  The vasohibin-1 
scores of OA and RA synovial tissues were 1.31±
0.42 and 2.17±0.7,  respectively (Fig.  1B).  The 
vasohibin-1 score was signiﬁcantly diﬀerent between 
the two groups (p＝0.0048).  The inﬂammation score 
was positively and signiﬁcantly correlated with the 
vasohibin-1 score in the RA synovium (r＝0.842,  p＝
0.002,  n＝12),  but not in the OA synovium (r＝0.842,  
p＝0.09,  n＝9; Fig.  1C).  These results suggest that 
vasohibin-1 is preferentially expressed in the RA 
synovium,  in association with the severity of inﬂam-
mation.
　 Expression of VEGF in OA and RA synovial 
tissues. Marked immunoreactivity for VEGF was 
observed in inﬁltrating cells,  and lesser VEGF immu-
noreactivity was seen in synovial lining cells,  synovial 
ﬁbroblasts,  and endothelial cells in the RA synovium 
(Fig.  2A).  The VEGF scores of OA and RA synovial 
tissues were 1.47±0.53 and 2.30±0.88,  respec-
tively,  and these values were signiﬁcantly diﬀerent (p
＝0.02,  Fig.  2B).  In the synovial samples from 
patients with RA,  the VEGF score was positively and 
signiﬁcantly correlated with the vasohibin-1 score (r
＝0.736,  p＝0.005; Fig.  2C).  These results suggest 
that VEGF was up-regulated in the RA synovium,  in 
association with the levels of vasohibin-1.
　 CD34-positive microvessel density in the OA 
and RA synovium. The immunohistochemical 
analysis revealed the presence of CD34-positive endo-
thelial cells in blood vessels in the OA and RA syn-
ovium (Fig.  3A).  The CD34-positive microvessel 
densities (vessel number per×100 ﬁeld) were not 
statistically diﬀerent between OA and RA (19.2±
11.9 and 24.5±11.0,  respectively; p＝0.30; Fig.  
3B).  In the RA synovial samples,  the microvessel 
density was not signiﬁcantly correlated with the vaso-
hibin-1 score (r＝0.542,  p＝0.069; Fig.  3C).  Thus 
the microvessel density was not associated with the 
expression of vasohibin-1in the RA synovium,  in con-
trast to the levels of VEGF,  which exhibited a posi-
tive correlation with vasohibin-1 expression.
　 VEGF-stimulated expression of vasohibin-1 
in RASFs. We next examined the potential induc-
tion of vasohibin-1 by VEGF under normoxia or 
hypoxia in RASFs.  RASFs were stimulated with 
VEGF (0.1 and 1.0nM) for the indicated periods and 
real-time PCR was performed to investigate vaso-
hibin-1 mRNA expression.  The levels of vasohibin-1 
mRNA were signiﬁcantly increased by VEGF at 48h 
under normoxia by 0.1nM of VEGF,  but not under a 
hypoxic condition (Fig.  4).  Dose-dependent eﬀects of 
VEGF on the levels of vasohibin-1 mRNA were not 
observed under either a normoxic or hypoxic condition 
(Fig.  4).
　 Cytokine-stimulated expression of vaso-
hibin-1 in RASFs. We next examined the poten-
tial induction of vasohibin-1 by inﬂammatory cytokines 
in RASFs.  Stimulation of RASFs with TNF-α (1ng/
ml) signiﬁcantly down-regulated vasohibin-1 mRNA 
expression at 12-48h under a normoxic condition (p＜
0.01).  Stimulation by IL-1β (10ng/ml) under a nor-
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Table 2　 The synovial inﬂammation score of the OA and RA synovial membrane (mean±SD).  The inﬂammation score was signiﬁcantly 
diﬀerent between the two groups (p＜0.003).  ＊p＜0.05 vs. OA.  ＊＊p＜0.01 vs. OA.
Synovial lining cell
hyperplasia
Cellular
inﬁltration
Fibrosis of the 
lining cell layer
Inﬂammation score
(total)
OA 0.47±0.35　 0.98±0.49　　 1.16±0.34　　 2.60±0.94　　
RA 1.22±0.83＊ 2.32±0.95＊＊ 2.15±0.62＊＊ 5.68±1.96＊＊
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moxic condition down-regulated vasohibin-1 expression 
at 48h (p＜0.01).  Stimulation by the combination of 
IL-1β (10ng/ml) and TNF-α (1ng/ml) under a nor-
moxic condition also down-regulated vasohibin-1 
expression at 48h (p＜0.01) (Fig.  5A).  Under a 
hypoxic condition,  TNF-α (1ng/ml) stimulation did not 
up-regulate vasohibin-1 expression.  However,  IL-1β 
(10ng/dl) stimulation under a hypoxic condition up-
regulated vasohibin-1 expression at 12h (p＜0.05),  
and signiﬁcantly down-regulated vasohibin-1 expres-
sion at 48h (p＜0.01).  Stimulation by the combination 
of IL-1β (10ng/ml) and TNF-α (1ng/ml) under a 
hypoxic condition further enhanced the mRNA expres-
sion of vasohibin-1 (Fig.  5B) up to 24h (p＜0.05;  
Fig.  5B).
　Cytokine-stimulated expression of VEGF in 
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Fig. 1　 A,  Comparison of the histologic features of synovial samples derived from patients with rheumatoid arthritis (RA) and osteoar-
thritis (OA).  Immunohistochemical analysis was performed to detect vasohibin-1 in OA and RA synovial samples.  In OA samples,  immu-
noreactivity for vasohibin-1 was observed in a few endothelial cells (arrows).  In RA samples,  immunoreactivity for vasohibin-1 was 
observed in synovial lining cells (arrowheads),  endothelial cells (arrows),  synovial ﬁbroblasts,  and inﬁltrating inﬂammatory cells.  In OA 
samples,  the inﬂammation score was 2 (synovial lining cell hyperplasia 0,  cellular inﬁltration 0,  ﬁbrosis of the lining cell layer 2),  the 
vasohibin-1 score 1,  and the VEGF score 1.  In the RA samples,  the inﬂammation score was 10 (synovial lining cell hyperplasia 2,  cellular 
inﬁltration 4,  ﬁbrosis of the lining cell layer 4),  the vasohibin-1 score 3,  and the VEGF score 4; B,  The vasohibin-1 score of synovial tis-
sues.  The vasohibin-1 scores of OA and RA synovial tissues were 1.31±0.42 and 2.17±0.7,  respectively (＊p＝0.0048),  as determined 
by the method described in the Materials and Methods.  The values in each column are the means±SD; C,  Correlation between inﬂam-
mation scores and vasohibin-1 scores. The inﬂammation score was also positively correlated with the vasohibin-1 score in the RA synovium 
(r＝0.842,  p＝0.002,  n＝12),  but not in the OA synovium (r=0.842,  p＝0.09,  n＝9).
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RASFs. We next examined the levels of VEGF 
mRNA in RASFs by stimulation with cytokines under 
a normoxic or hypoxic condition.  VEGF mRNA 
expression was not up-regulated by TNF-α (1ng/ml),  
but was up-regulated by IL-1β (10ng/ml) under a 
normoxic condition.  Stimulation of the cells by the 
combination of IL-1β (10ng/ml) and TNF-α (1ng/ml) 
under a normoxic condition also enhanced mRNA 
expression of VEGF (Fig.  6A).  VEGF expression 
was markedly up-regulated by TNF-α (1ng/ml) or 
IL-1β (10ng/ml) under a hypoxic condition.  Stimula-
tion of the cells by the combination of IL-1β (10ng/
ml) and TNF-α (1ng/ml) under a hypoxic condition 
also markedly enhanced the mRNA expression of 
VEGF (Fig.  6B).
Discussion
　 Angiogenesis plays a key role in normal vascular 
development,  is a decisive factor in cancer,  wound 
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Fig. 2　 A,  Immunohistochemistry for VEGF in synovial samples from patients with OA and RA.  In OA samples,  immunoreactivity for 
vasohibin-1 was observed in a few synovial lining cells (arrowheads) or endothelial cells (arrows).  In RA samples,  immunoreactivity for 
VEGF was strongly observed in inﬁltrating cells,  synovial lining cells (arrowheads),  synovial ﬁbroblasts,  and endothelial cells (arrows); B,  
The VEGF score of synovial tissues.  The VEGF scores of RA and OA synovial tissues were 1.47±0.53 and 2.30±0.88,  respectively,  and 
these values were signiﬁcantly diﬀerent (＊p＝0.02),  as determined by the method described in the Materials and Methods.  The values in 
each column are the means±SD; C,  Correlation between VEGF scores and vasohibin-1 scores in the RA synovium (n＝12).  The VEGF 
score was positively correlated with the vasohibin-1 score (r＝0.736,  p＝0.005).
6
Acta Medica Okayama, Vol. 63 [2009], Iss. 6, Art. 6
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss6/6
healing,  and inﬂammation [25],  and is regulated by 
the local balance between angiogenic stimulators and 
inhibitors.  As the pathogenesis of RA is highly inﬂu-
enced by angiogenesis in the process of forming and 
maintaining inﬂammatory synovial tissues,  the applica-
tion of angiogenesis inhibitors for the treatment of RA 
has been expected.  A number of angiogenesis inhibi-
tors have been investigated and identiﬁed,  including 
angiostatin,  endostatin,  platelet factor-4 (PF4),  
thrombospondin-1 (TSP-1) [26] and tumstatin [27].  
Vasohibin-1 is a newly identiﬁed negative feedback 
regulator of angiogenesis.  In humans,  the levels of 
vasohibin-1 have been investigated in angiogenesis-
associated disorders such as endometrial cancer,  or in 
choroidal neovascular membranes [15,  28],  and a 
potential association with disease activity was demon-
strated.  The results of the immunohistochemistry in 
the present study suggested that vasohibin-1 is 
expressed in synovial lining cells,  endothelial cells,  
and synovial ﬁbroblasts in RA synovial tissue.  The 
intensity of the immunoreactivity for vasohibin-1 was 
correlated with the inﬂammation score and VEGF 
score,  and was signiﬁcantly higher in the RA syn-
ovium than the OA synovium.  In fact,  Tamaki et al.  
demonstrated an association between vasohibin-1 
expression and inﬂammation in human breast lesions 
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[16],  consistent with the present results in patients 
with RA.  On the other hand,  the vessel densities in 
synovial tissue in patients with RA were not signiﬁ-
cantly diﬀerent from those in patients with OA as 
detected by immunohistochemistry for CD34,  proba-
bly because blood vessels may not be easily eliminated 
even after the suspension of inﬂammatory stimuli.
　 Hypoxia caused by synovial inﬂammation in RA 
stimulates HIF.  In their immunohistochemical analy-
sis,  Hollander et al.  observed that HIF-1α was up-
regulated in synovial CD68＋ macrophages prepared 
from biopsy samples of patients with RA and OA in 
comparison with healthy controls [29].  In addition,  
Manabe et al.  demonstrated that inﬂammatory cytok-
ines further induced HIF-1 expression in RASFs in 
vitro [23].  Since HIF induces the expression of a 
broad range of pro-angiogenic factors,  hypoxia and 
inﬂammatory cytokines are closely associated with 
angiogenesis in RA.  Previous reports utilizing 
HUVEC demonstrated that vasohibin-1 expression was 
up-regulated by exogenous VEGF in a time and con-
centration-dependent manner [13].  Interestingly,  
hypoxia is known to act as a trigger of both physio-
logical and pathological angiogenesis by inducing 
VEGF,  mediated via HIF [30,  31].  However,  a 
previous study reported that hypoxia did not aﬀect the 
expression of vasohibin-1,  and rather inhibited up-
regulation of vasohibin-1 mRNA as well as protein 
levels upon stimulation by VEGF in ECs [13].  Our 
results demonstrated that up-regulation of vasohibin-1 
was abolished under a hypoxic condition in RASFs,  
consistent with previous ﬁndings in ECs.  On the other 
hand,  the expression of vasohibin-1 was down-regu-
lated by inﬂammatory cytokines (e.g.,  TNF-α and IL-1) 
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Fig. 5　 A,  Time course of the eﬀects of cytokines on the expression of vasohibin-1 mRNA (normoxia).  Cells were stimulated with TNF-
α (1ng/ml) and/or IL-1β (10ng/ml) for 48h under a normoxic condition as described in the Materials and Methods.  Stimulation by cytok-
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Materials and Methods.  IL-1β with and without TNF-α signiﬁcantly up-regulated vasohibin-1 expression at 24h, and TNF-α or IL-1β down-
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alone and was further down-regulated in the presence 
of VEGF in ECs [13,  32].  In the present study,  the 
expression of vasohibin-1 in RASFs was down-regu-
lated by stimulation with TNF-α or IL-1β under nor-
moxia,  consistent with the results observed in ECs 
[13].  However,  the levels of VEGF mRNA were 
markedly increased by TNF-α and IL-1β under a 
hypoxic condition,  accompanied by an increase in 
vasohibin-1 mRNA.  The discrepancy in regard to the 
response to cytokines under hypoxia between endothe-
lial cells and RASFs may be,  at least in part,  attrib-
uted to the distinct cell-types.  On the other hand,  
Shen et al.  reported that increased expression of 
VEGF in the ischemic retina was accompanied by 
increased levels of vasohibin-1 mRNA in a murine 
retinal neovascular model [19].  Sato et al.  observed 
a statistically signiﬁcant correlation between the vitre-
ous concentration of vasohibin-1 and VEGF in patients 
with proliferative diabetic retinopathy [17].  These 
results suggest that increased “endogenous” VEGF 
induced by hypoxia in combination with inﬂammatory 
cytokines may up-regulate vasohibin-1 expression in 
spite of the hypoxic condition,  as observed in the RA 
synovium and in proliferative retinopathy.
　 Since the expression of vasohibin-1 was correlated 
with inﬂammation,  the biological roles of vasohibin-1 
in regulating anti-angiogenic activity in inﬂammation of 
the synovium and joint destruction would seem to be an 
attractive research topic.  Shen et al.  reported that 
intraocular injection of recombinant vasohibin-1 or an 
adenoviral vector containing a vasohibin-1 expression 
cassette strongly suppressed retinal neovasculariza-
tion in mice with ischemic retinopathy [19].  Sato et 
al.  reported that transfection of Lewis lung carcinoma 
(LCC) cells with the vasohibin-1 gene did not aﬀect the 
proliferation of cancer cells in vitro,  but did inhibit 
tumor growth and tumor angiogenesis in vivo [13].  
Thus,  the therapeutic application of vasohibin-1 tar-
geting VEGF and angiogenesis in animal models of RA 
may clarify the biological role of this factor in the 
progression of rheumatoid arthritis.
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